Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | -3.23% | -6.57% | -6.57% |
12/02 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
07/02 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.57% | 2.62Cr | |
+31.37% | 59TCr | |
-2.60% | 36TCr | |
+20.83% | 33TCr | |
+5.69% | 29TCr | |
+14.83% | 24TCr | |
+9.93% | 21TCr | |
-6.95% | 20TCr | |
+10.77% | 17TCr | |
+0.10% | 16TCr |
- Stock Market
- Equities
- ACST Stock
- News Acasti Pharma Inc.
- Acasti Pharma Says it has Aligned With FDA Protocol for Phase 3 Trial of GTX-104; Receives New Drug Application Guidance